Details
Stereochemistry | ACHIRAL |
Molecular Formula | C2H4O2 |
Molecular Weight | 60.052 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(O)=O
InChI
InChIKey=QTBSBXVTEAMEQO-UHFFFAOYSA-N
InChI=1S/C2H4O2/c1-2(3)4/h1H3,(H,3,4)
DescriptionSources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022041s008s009lbl.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39de0239-a4f6-45b0-a3cf-c6fba941c08eCurator's Comment: description was created based on several sources, including
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022041s008s009lbl.pdfhttps://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=39de0239-a4f6-45b0-a3cf-c6fba941c08e
Curator's Comment: description was created based on several sources, including
Acetic acid (a component of vinagre) is used in medicine for the treatment of otitis externa caused by bacterial infections. The solution containing acetic acid was approved by FDA.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14668053https://www.ncbi.nlm.nih.gov/pubmed/2117062
Curator's Comment: Acetic acid was shown to cross the blood brain barrier in rats.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: cyanide ions |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | CYANOKIT Approved UseCyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. (1.1) If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. (1.2) The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. (1.2) 1.1 Indication Cyanokit is indicated for the treatment of known or suspected cyanide poisoning. 1.2 Identifying Patients with Cyanide Poisoning Cyanide poisoning may result from inhalation, ingestion, or dermal exposure to various cyanide-containing compounds, including smoke from closed-space fires. Sources of cyanide poisoning include hydrogen cyanide and its salts, cyanogenic plants, aliphatic nitriles, and prolonged exposure to sodium nitroprusside. The presence and extent of cyanide poisoning are often initially unknown. There is no widely available, rapid, confirmatory cyanide blood test. Treatment decisions must be made on the basis of clinical history and signs and symptoms of cyanide intoxication. If clinical suspicion of cyanide poisoning is high, Cyanokit should be administered without delay. Table 1 Common Signs and Symptoms of Cyanide Poisoning Symptoms Signs Headache Altered Mental Status (e.g., confusion,disorientation) Confusion Seizures or Coma Dyspnea Mydriasis Chest tightness Tachypnea / Hyperpnea (early) Nausea Bradypnea / Apnea (late) Hypertension (early) / Hypotension (late) Cardiovascular collapse Vomiting Plasma lactate concentration ≥ 8 mmol/L In some settings, panic symptoms including tachypnea and vomiting may mimic early cyanide poisoning signs. The presence of altered mental status (e.g., confusion and disorientation) and/or mydriasis is suggestive of true cyanide poisoning although these signs can occur with other toxic exposures as well. The expert advice of a regional poison control center may be obtained by calling 1-800-222-1222. Smoke Inhalation Not all smoke inhalation victims will have cyanide poisoning and may present with burns, trauma, and exposure to other toxic substances making a diagnosis of cyanide poisoning particularly difficult. Prior to administration of Cyanokit, smoke-inhalation victims should be assessed for the following: Exposure to fire or smoke in an enclosed area Presence of soot around the mouth, nose or oropharynx Altered mental status Although hypotension is highly suggestive of cyanide poisoning, it is only present in a small percentage of cyanide-poisoned smoke inhalation victims. Also indicative of cyanide poisoning is a plasma lactate concentration ≥ 10 mmol/L (a value higher than that typically listed in the table of signs and symptoms of isolated cyanide poisoning because carbon monoxide associated with smoke inhalation also contributes to lactic acidemia). If cyanide poisoning is suspected, treatment should not be delayed to obtain a plasma lactate concentration. 1.3 Use with Other Cyanide Antidotes Caution should be exercised when administering other cyanide antidotes simultaneously with Cyanokit, as the safety of co-administration has not been established. If a decision is made to administer another cyanide antidote with Cyanokit, these drugs should not be administered concurrently in the same intravenous line. [see Dosage and Administration (2.3) Launch Date2006 |
|||
Curative | VOSOL Approved UseFor the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial. Launch Date1960 |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4511.6 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8699553 |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXOCOBALAMIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
26.2 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/8699553 |
5 g single, intravenous dose: 5 g route of administration: Intravenous experiment type: SINGLE co-administered: |
HYDROXOCOBALAMIN plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg 1 times / day multiple, intramuscular Dose: 20 mg, 1 times / day Route: intramuscular Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy, 13 years |
|
20 g single, intravenous Highest studied dose Dose: 20 g Route: intravenous Route: single Dose: 20 g Sources: |
unhealthy, 26.9 years Health Status: unhealthy Age Group: 26.9 years Sex: M Sources: |
|
5 g single, intravenous Overdose |
unhealthy, 3 years |
|
5 g single, intravenous |
unhealthy, 62 years |
|
2000 ug 2 times / day multiple, oral Dose: 2000 ug, 2 times / day Route: oral Route: multiple Dose: 2000 ug, 2 times / day Sources: |
unhealthy, adult |
PubMed
Title | Date | PubMed |
---|---|---|
Microbiological degradation of diazepam. | 1975 |
|
Modification of drug action by hyperammonemia. | 1984 Apr |
|
Prevention of methionine and ammonia-induced coma by intravenous infusion of a branched chain amino acid solution to rats with liver injury. | 1984 Oct |
|
Disruption of the blood-brain barrier in hyperammonemic coma and the pharmacologic effects of dexamethasone and difluoromethyl ornithine. | 1985 |
|
Carbon-arsenic bond cleavage by a newly isolated gram-negative bacterium, strain ASV2. | 1995 Mar |
|
Acceleration of ulcer healing by cholecystokinin (CCK): role of CCK-A receptors, somatostatin, nitric oxide and sensory nerves. | 1999 Jun 30 |
|
Evidence for activation of the tissue kallikrein-kinin system in nociceptive transmission and inflammatory responses of mice using a specific enzyme inhibitor. | 2000 Jul |
|
Acetyl-CoA synthetase 2, a mitochondrial matrix enzyme involved in the oxidation of acetate. | 2001 Apr 6 |
|
Exploring infection of wheat and carbohydrate metabolism in Mycosphaerella graminicola transformants with differentially regulated green fluorescent protein expression. | 2001 Feb |
|
In vivo (13)C NMR measurement of neurotransmitter glutamate cycling, anaplerosis and TCA cycle flux in rat brain during. | 2001 Feb |
|
Metabolic shifts and myocyte hypertrophy in deflazacort treatment of mdx mouse cardiomyopathy. | 2001 Feb |
|
In silico predictions of Escherichia coli metabolic capabilities are consistent with experimental data. | 2001 Feb |
|
Structure of manganese diacetate tetrahydrate and low-temperature methyl-group dynamics. | 2001 Feb |
|
Development of xylose-fermenting yeast Pichia stipitis for ethanol production through adaptation on hardwood hemicellulose acid prehydrolysate. | 2001 Feb |
|
Screening for cervical neoplasia in a developing country utilizing cytology, cervicography and the acetic acid test. | 2001 Feb |
|
Evidence that cyproterone acetate improves psychological symptoms and enhances the activity of the dopaminergic system in postmenopause. | 2001 Feb |
|
Protein kinase C phosphorylates RGS2 and modulates its capacity for negative regulation of Galpha 11 signaling. | 2001 Feb 23 |
|
Computational studies on nonenzymatic and enzymatic pyridoxal phosphate catalyzed decarboxylations of 2-aminoisobutyrate. | 2001 Feb 6 |
|
Long-term stability characterization of a controlled release gastrointestinal therapeutic system coated with a cellulose acetate pseudolatex. | 2001 Jan |
|
Effect of ruminal vs postruminal administration of degradable protein on utilization of low-quality forage by beef steers. | 2001 Jan |
|
Measurement of myocardial blood flow with PET using 1-11C-acetate. | 2001 Jan |
|
Immunobiology of the reproductive tract in a female baboon. | 2001 Jan |
|
Analgesic activity of Peperomia pellucida aerial parts in mice. | 2001 Jan |
|
Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate. | 2001 Jan |
|
Effects of zinc acetate on splenocytes of endotoxemic mice: enhanced immune response, reduced apoptosis, and increased expression of heat shock protein 70. | 2001 Jan |
|
Inactivation of infective larvae of Angiostrongylus costaricensis with short time incubations in 1.5% bleach solution, vinegar or saturated cooking salt solution. | 2001 Jan 15 |
|
Modelling the influence of pH and organic acid types on thermal inactivation of Bacillus cereus spores. | 2001 Jan 22 |
|
[DOTA-bis(amide)]lanthanide complexes: NMR evidence for differences in water-molecule exchange rates for coordination isomers. | 2001 Jan 5 |
|
Succinic acid production with reduced by-product formation in the fermentation of Anaerobiospirillum succiniciproducens using glycerol as a carbon source. | 2001 Jan 5 |
|
p300 does not require its acetylase activity to stimulate p73 function. | 2001 Jan 5 |
|
The mechanism of beta-hematin formation in acetate solution. Parallels between hemozoin formation and biomineralization processes. | 2001 Jan 9 |
|
Metabolic fate of [14C]-ethanol into endothelial cell phospholipids including platelet-activating factor, sphingomyelin and phosphatidylethanol. | 2001 Jan-Feb |
|
S-methyl-N,N-diethylthiocarbamate sulfoxide elicits neuroprotective effect against N-methyl-D-aspartate receptor-mediated neurotoxicity. | 2001 Jan-Feb |
|
Salt accumulation resulting from base added for pH control, and not ethanol, limits growth of Thermoanaerobacteriumthermosaccharolyticum HG-8 at elevated feed xylose concentrations in continuous culture. | 2001 Jan-Feb |
|
Conversion of sugars to 1,2-propanediol by Thermoanaerobacterium thermosaccharolyticum HG-8. | 2001 Jan-Feb |
|
Characterization of bioreaction processes: aerobic Escherichia coli cultures. | 2001 Nov 30 |
|
Acute ammonia intoxication induces an NMDA receptor-mediated increase in poly(ADP-ribose) polymerase level and NAD metabolism in nuclei of rat brain cells. | 2004 Jun |
|
[Antioxidant enzymes of the rat liver, brain, heart and erythrocytes in ammonia intoxication]. | 2005 Mar-Apr |
|
Effects of acute ammonia toxicity on nitric oxide (NO), citrulline-NO cycle enzymes, arginase and related metabolites in different regions of rat brain. | 2005 Oct |
|
AMP deaminase and adenosine deaminase activities in liver and brain regions in acute ammonia intoxication and subacute toxic hepatitis. | 2010 Jan 22 |
|
Effects of ammonia and allopurinol on rat hippocampal NMDA receptors. | 2010 Mar |
|
Direct exposure to ammonia and hyperammonemia increase the extracellular accumulation and degradation of astroglia-derived glutathione in the rat prefrontal cortex. | 2010 Sep |
Patents
Sample Use Guides
Cyanokit (hydroxocobalamin for injection): one 5 g vial is a complete starting dose
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6692038
Curator's Comment: Hydroxocobalamin (OH-Cbl), when used to treat vitamin B12 deficiency, is better retained by the body than is cyanocobalamin (CN-Cbl), but the availability to cells has not been studied systematically. In a series of experiments, were compared the uptake and internalization of OH-Cbl and CN-Cbl bound to transcobalamin II (TCII) by a human cell model, the HeLa cell. TCII-OH-Cbl was: (1) taken up in larger amounts per unit time, (2) the greater uptake was not a consequence of more effective attachment to receptors of TCII-Cbl nor to a more rapid regeneration of receptors, (3) the difference was expressed during the phase of internalization of TCII-Cbl, (4) with CN-Cbl, the stages of binding to receptors plus internalization were more readily reversed, and (5) larger amounts of OH-Cbl were internalized and converted to active coenzyme forms of Cbl.
Unknown
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 447
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1025
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1081
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 323
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1247
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 724
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
28
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-ATC |
S02AA10
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
JECFA EVALUATION |
ACETIC ACID
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 879
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
NCI_THESAURUS |
C254
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
FDA ORPHAN DRUG |
706219
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-ATC |
G01AD02
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-VATC |
QG01AD02
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1144
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
DSLD |
396 (Number of products:5)
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1096
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 951
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1236
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
CFR |
21 CFR 184.1005
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 908
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 728
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 993
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
CODEX ALIMENTARIUS (GSFA) |
INS-260
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1035
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 887
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1132
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
WHO-VATC |
QS02AA10
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1089
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 880
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 561
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 140
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
JECFA EVALUATION |
INS-260
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1082
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 801
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 1094
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
15366
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
Acetic acid (medical use)
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
406306
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
ACETIC ACID
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
168
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | RxNorm | ||
|
DTXSID5024394
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
200-580-7
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
1005706
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
100000088999
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
4211
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
ACETIC ACID
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | Description: Clear, colourless liquids. At a temperature below 15 ?C Glacial acetic acid may occur as a translucent, crystalline mass; odour, characteristic and pungent. Miscibility: Miscible with water, ethanol (~750 g/l) TS, and glycerol R. Category: Acidifying agent. Storage: Acetic acid should be kept in a tightly closed container. Additional information: Glacial acetic acid is flammable and should be handled with care. Congealing point, about 15 ?C. | ||
|
D019342
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
SUB11689MIG
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
CHEMBL539
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
3
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
176
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
127175
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
64-19-7
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
C61623
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
112209
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
m1324
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | Merck Index | ||
|
39
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
132953
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
463-83-2
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
ALTERNATIVE | |||
|
Q40Q9N063P
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
DB03166
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
115870
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
SUB12711MIG
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
Q40Q9N063P
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY | |||
|
111201
Created by
admin on Mon Mar 31 17:47:13 GMT 2025 , Edited by admin on Mon Mar 31 17:47:13 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
PARENT (METABOLITE)
PARENT (METABOLITE)